Favitab-200

Moderate cases of COVID-19

Antiviral

Favipiravir is a new antiviral drug against influenza. It is metabolized into favipiravir ribosyl triphosphate (favipiravir RTP) by an intracellular enzyme, and favipiravir RTP selectively inhibits RNA polymerase (RNA-dependent RNA polymerase) of the influenza virus, preventing replication of the influenza virus. It is a drug with a mechanism of action different from that of the existing influenza antiviral drugs and effective against all types and sub-types of human influenza A, B, and C viruses in vitro, showing a wide range of anti-viral activity against various influenza virus strains including avian and swine viruses.

Day-1: 1600 mg in divided dose(4+0+4)

Day2-10: 600 mg BID (3+0+3)

In animal studies, decreased RBC production,and increases in liver function parameters such as AST, ALP, ALT and total bilirubin, and increased vacuolization in hepatocytes. Toxicity information regarding Favipiravir in humans is not readily available.

Favipiravir is contraindicated in women who might be or are pregnant and in lactating women because of its association with embryonic deaths and teratogenicity in animal studies (above) and that men should use the most effective contraceptive methods including condoms

The following clinically significant adverse reactions have been reported with other anti-influenza virus agents. Patients should be carefully monitored, and if any abnormality is observed, the treatment should be discontinued and appropriate measures should be taken. 1. Shock, anaphylaxis 2. Pneumonia 3. Hepatitis fulminant, hepatic dysfunction, jaundice 4. Toxic epidermal necrolysis (TEN), oculomucocutaneous syndrome (Stevens-Johnson syndrome) 5. Acute kidney injury 6. White blood cell count decreased, neutrophil count decreased, platelet count decreased 7. Neurological and psychiatric symptoms (consciousness disturbed, abnormal behavior, deliria, hallucination, delusion, convulsion, etc.) 8. Colitis haemorrhagic

Do not administer to women known or suspected to be pregnant. (Early embryonic deaths [rats] and teratogenicity [monkeys, mice, rats and rabbits] have been observed in animal studies with exposure levels similar to or lower than the clinical exposure.) (2) When administering to lactating women, instruct to stop lactating. (The major metabolite of Favipiravir, a hydroxylated form, was found to be distributed in breast milk.)

In animal studies, decreased RBC production,and increases in liver function parameters such as AST, ALP, ALT and total bilirubin, and increased vacuolization in hepatocytes. Toxicity information regarding Favipiravir in humans is not readily available.

Keep below 30°C temperature, protected from light & moisture. Keep out of the reach of children.

As per physician